Lower Serum Antibodies Against Tau Protein and Heavy Neurofilament in Alzheimer's Disease

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11110%2F18%3A10376805" target="_blank" >RIV/00216208:11110/18:10376805 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00216208:11120/18:43916903 RIV/00216208:11130/18:10376805 RIV/00064173:_____/18:N0000112 RIV/00064203:_____/18:10376805

Výsledek na webu

<a href="https://doi.org/10.3233/JAD-180039" target="_blank" >https://doi.org/10.3233/JAD-180039</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.3233/JAD-180039" target="_blank" >10.3233/JAD-180039</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Lower Serum Antibodies Against Tau Protein and Heavy Neurofilament in Alzheimer's Disease

Popis výsledku v původním jazyce

Background: Unlike antibodies against amyloid-beta, little is known about serum antibodies to neuron-specific cytoskeletal proteins in patients with Alzheimer&apos;s disease (AD). Objective: We aimed to study IgG autoantibodies against tau protein, light (NFL) and heavy subunits (NFH) of neurofilaments in serum of AD patients and elderly controls and to explore the evolution of antineurocytoskeletal antibody levels over time. Methods: Antibodies against three targets (tau, NFL, and NFH) were measured using ELISA in 100 serum samples from 51 cognitively normal elderly controls and 49 patients with AD. Our primary cross-sectional design was further extended to monitor fluctuations over 1-2 years in a subset of individuals. Results: The AD patients had lower levels of anti-tau antibodies (p = 0.03) and even lower anti-NFH antibodies (p = 0.005) than those in the control group at baseline. On the contrary, anti-NFL antibodies or total IgG concentrations in serum did not differ. All three antibodies remained stable in both groups except for a selective and significant anti-tau decline in AD patients (p = 0.03). Conclusions: The different responses to these antigens suggest some antibody selectivity in AD. The significant decline was observed for only serum anti-tau antibodies in AD patients over time and it corresponds to lower anti-tau levels in these patients. Our findings indicate a special feature of disease-relevant antigens and humoral autoimmunity in AD.

Název v anglickém jazyce

Lower Serum Antibodies Against Tau Protein and Heavy Neurofilament in Alzheimer's Disease

Popis výsledku anglicky

Background: Unlike antibodies against amyloid-beta, little is known about serum antibodies to neuron-specific cytoskeletal proteins in patients with Alzheimer&apos;s disease (AD). Objective: We aimed to study IgG autoantibodies against tau protein, light (NFL) and heavy subunits (NFH) of neurofilaments in serum of AD patients and elderly controls and to explore the evolution of antineurocytoskeletal antibody levels over time. Methods: Antibodies against three targets (tau, NFL, and NFH) were measured using ELISA in 100 serum samples from 51 cognitively normal elderly controls and 49 patients with AD. Our primary cross-sectional design was further extended to monitor fluctuations over 1-2 years in a subset of individuals. Results: The AD patients had lower levels of anti-tau antibodies (p = 0.03) and even lower anti-NFH antibodies (p = 0.005) than those in the control group at baseline. On the contrary, anti-NFL antibodies or total IgG concentrations in serum did not differ. All three antibodies remained stable in both groups except for a selective and significant anti-tau decline in AD patients (p = 0.03). Conclusions: The different responses to these antigens suggest some antibody selectivity in AD. The significant decline was observed for only serum anti-tau antibodies in AD patients over time and it corresponds to lower anti-tau levels in these patients. Our findings indicate a special feature of disease-relevant antigens and humoral autoimmunity in AD.

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

30103 - Neurosciences (including psychophysiology)

Projekt

—

Návaznosti

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2018

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Journal of Alzheimer&apos;s Disease

ISSN

1387-2877

e-ISSN

—

Svazek periodika

64

Číslo periodika v rámci svazku

3

Stát vydavatele periodika

NL - Nizozemsko

Počet stran výsledku

10

Strana od-do

751-760

Kód UT WoS článku

000437257500006

EID výsledku v databázi Scopus

2-s2.0-85049687560